cysteine/stroke

BACKGROUND OF THE INVENTION Field of the Invention The present invention relates generally to the use of .gamma.-glutamyl-D-cysteine as a cytoprotective agent to prevent reperfusion injury of the blood-brain barrier that may contribute to hemorrhagic transformation due to thrombolysis following an

FIELD OF THE INVENTION This invention relates to novel cysteine prodrugs and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the use of .gamma.-glutamyl antioxidants, particularly .gamma.-glutamyl -cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the use of .gamma.-glutamyl antioxidants, particularly .gamma.-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel sulfonamide derivative. More particularly, it relates to a novel sulfonamide derivative or a salt thereof which shows a strong inhibitory activity against cysteine protease such as calpain, cathepsin B,

FIELD OF THE INVENTION The invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme. The invention also relates to pharmaceutical compositions comprising a compound of the present invention. The invention also relates to methods of treating stroke, inflammatory

BACKGROUND OF THE INVENTION Cysteine proteases have been viewed as lysosomal mediators of terminal protein degradation. Several newly discovered members of this enzyme class, however, are regulated proteases with limited tissue expression, which implies specific roles in cellular physiology and thus

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates generally to protease inhibitors and applications thereof, more specifically to peptide inhibitors of cysteine proteases, even more specifically to aza-peptide epoxides, methods of their use, and methods of their

FIELD OF THE INVENTION The present invention relates to novel beta-amino acid nitrile derivatives, their manufacture and use as medicaments. In particular, the invention relates to novel beta-amino acid nitrile derivatives of formula (I) ##STR1## wherein R.sup.1 represents hydrogen, aryl,

FIELD OF THE INVENTION The present invention relates to compositions comprising semi synthetic biologic molecules which are bioconjugates of an APJ agonist polypeptide and a fatty acid moiety. In particular, the bioconjugates of the invention, while retaining APJ agonistic activity, exhibit greater